Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Wild Type ◽

Open Label ◽

SPIRITT: A multicenter, open-label, randomized, phase II clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with metastatic colorectal cancer (mCRC) with wild-type KRAS tumors.

10.1200/jco.2010.28.15_suppl.tps195 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS195-TPS195

Author(s):

A. L. Cohn ◽

K. Krishnan ◽

J. R. Hecht

Keyword(s):

Colorectal Cancer ◽

Clinical Trial ◽

Phase Ii ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Open Label ◽

Safety And Efficacy ◽

An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer

10.1200/jco.2005.23.16_suppl.3583 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3583-3583 ◽

Cited By ~ 22

Author(s):

A. L. A. Fields ◽

D. A. Rinaldi ◽

C. A. Henderson ◽

C. J. Germond ◽

L. Chu ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Second Line ◽

Open Label ◽

Second Line Therapy ◽

Multicenter Phase ◽

Line Therapy

PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS.

10.1200/jco.2010.28.15_suppl.tps189 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS189-TPS189

Author(s):

L. S. Schwartzberg ◽

V. J. Wagner

Keyword(s):

Colorectal Cancer ◽

Unresectable Metastatic Colorectal Cancer

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).

10.1200/jco.2014.32.15_suppl.tps3662 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3662-TPS3662

Author(s):

Kohei Shitara ◽

Kentaro Yamazaki ◽

Hiroyuki Uetake ◽

Takeshi Kato ◽

Eiji Oki ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Previously Treated

A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC).

10.1200/jco.2014.32.15_suppl.tps3649 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3649-TPS3649 ◽

Cited By ~ 2

Author(s):

Josep Tabernero ◽

Nicoletta Brega ◽

Craig Davis ◽

Ashwin Gollerkeri ◽

Kristen Pierce ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Study ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Wild Type ◽

Phosphatidylinositol 3 Kinase ◽

Predictive value of primary tumor location: Results from randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in patients with KRAS exon2 wild-type metastatic colorectal cancer (WJOG6510G)

Annals of Oncology ◽

10.1093/annonc/mdx393.109 ◽

2017 ◽

Vol 28 ◽

pp. v198

Author(s):

T. Tamura ◽

D. Sakai ◽

N. Sugimoto ◽

S. Tokunaga ◽

A. Tsuji ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Primary Tumor ◽

Predictive Value ◽

Phase Ii Study ◽

Tumor Location ◽

Wild Type ◽

Primary Tumor Location ◽

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

Annals of Oncology ◽

10.1093/annonc/mdw412 ◽

2016 ◽

Vol 27 (12) ◽

pp. 2216-2224 ◽

Cited By ~ 14

Author(s):

M. Moore ◽

S. Gill ◽

T. Asmis ◽

S. Berry ◽

R. Burkes ◽

...

Keyword(s):

Colorectal Cancer ◽

Disease Progression ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

First Line ◽

Second Line Therapy ◽

Line Therapy ◽

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

BMC Cancer ◽

10.1186/s12885-018-4001-x ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 3

Author(s):

Francesca Battaglin ◽

Marta Schirripa ◽

Federica Buggin ◽

Filippo Pietrantonio ◽

Federica Morano ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

Colorectal Cancer Patients

LBA-09 Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab

Annals of Oncology ◽

10.1093/annonc/mdv262.09 ◽

2015 ◽

Vol 26 ◽

pp. iv120 ◽

Cited By ~ 6

Author(s):

F. Ciardiello ◽

N. Normanno ◽

E. Martinelli ◽

T. Troiani ◽

C. Cardone ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

Abstract CT110: Randomized phase II study of duligotuzumab + FOLFIRI versus cetuximab + FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)

10.1158/1538-7445.am2015-ct110 ◽

2015 ◽

Cited By ~ 8

Author(s):

Andrew G. Hill ◽

Michael Findlay ◽

Matthew Burge ◽

Christopher Jackson ◽

Pilar Garcia Alfonso ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽